Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease

被引：14
|
作者：
Josting, A
Engert, A
Diehl, V
Canellos, GP
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] German Hodgkin Lymphoma Study Grp, Cologne, Germany
[3] Dana Faber Canc Inst, Dept Adult Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷
关键词：
D O I：
10.1093/annonc/13.S1.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：112 / 116
页数：5
相关论文
共 50 条
  • [1] Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors
    Canellos, GP
    ANNALS OF ONCOLOGY, 1998, 9 : 91 - 96
  • [2] Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma - A report from the German Hodgkin's Lymphoma Study Group.
    Josting, A
    Rueffer, U
    Franklin, J
    Sieber, M
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 514A - 514A
  • [3] Prognostic factors and treatment outcome in childhood Hodgkin disease
    Oguz, A
    Karadeniz, C
    Okur, FV
    Citak, EC
    Pinarli, FG
    Bora, H
    Akyurek, N
    PEDIATRIC BLOOD & CANCER, 2005, 45 (05) : 670 - 675
  • [4] Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group
    Josting, A
    Rueffer, U
    Franklin, J
    Sieber, M
    Diehl, V
    Engert, A
    BLOOD, 2000, 96 (04) : 1280 - 1286
  • [5] Prognostic Factors and Prognostic Score of Relapsed Hodgkin's Lymphoma
    Filatova, L. V.
    Tarasenkova, A. A.
    Gershanovich, M. L.
    Semiglazova, T. Y.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S276 - S276
  • [6] Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    Kewalramani, T
    Nimer, SD
    Zelenetz, AD
    Malhotra, S
    Qin, J
    Yahalom, J
    Moskowitz, CH
    BONE MARROW TRANSPLANTATION, 2003, 32 (07) : 673 - 679
  • [7] Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    T Kewalramani
    S D Nimer
    A D Zelenetz
    S Malhotra
    J Qin
    J Yahalom
    C H Moskowitz
    Bone Marrow Transplantation, 2003, 32 : 673 - 679
  • [8] Prognostic factors, treatment, and outcome in SLE patients with non-hodgkin's lymphoma
    Bernatsky, S. R.
    Gordon, C.
    Nived, O.
    Sturfelt, G.
    Bae, S.
    Gascoyne, R.
    Ramsey-Goldmans, R.
    Clarke, A. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 456 - 457
  • [9] Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma
    Goranova-Marinova, V. S.
    Ignatova, K.
    Ganeva, P.
    Spasov, E.
    Arnaudov, G.
    Micheva, I.
    Gercheva, L.
    Radinov, A.
    Petrova, R.
    Tzvetkova, G.
    Hadzhiev, E.
    Bogdanov, L.
    Tzvetkov, N.
    Spasov, B.
    Grudeva-Popova, Z.
    Tumbeva, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Treatment of relapsed Hodgkin's disease
    Gause, BL
    Longo, DL
    BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (03): : 559 - 572
12345